Login to Your Account

Deals And M&A NEWS

Amgen Inc. took a global exclusive license, with an option on a second, to develop and commercialize cardiovascular treatments using the subcutaneous RNAi delivery platform developed by Arrowhead Pharmaceuticals Inc.

Newly formed Seelos Therapeutics Inc. is "pretty well positioned to raise money," Ligand Pharmaceuticals Inc. President Matthew Foehr told BioWorld Today, and that's what Seelos needs to do in the four-piece licensing deal with San Diego-based Ligand.

The Medicines Co. and Roche AG unit Hoffmann-Laroche Inc. are joining the effort launched by BARDA to develop products to combat the emerging threat of multidrug-resistant bacterial infections, superbugs.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: